RT Journal Article SR Electronic T1 Chemotherapeutic dose scheduling based on tumor growth rates: the case for low dose metronomic high entropy therapies JF bioRxiv FD Cold Spring Harbor Laboratory SP 166058 DO 10.1101/166058 A1 West, Jeffrey A1 Newton, Paul K. YR 2017 UL http://biorxiv.org/content/early/2017/07/19/166058.abstract AB We extend classical tumor regression models, such as the Norton-Simon hypothesis, from instantaneous regression rates (i.e. the derivative) to the cumulative effect (i.e. the integral) over one (or many) cycles of chemotherapy. To achieve this end, we use a stochastic Moran process model of tumor cell kinetics, coupled with a prisoner’s dilemma game-theoretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrast maximum tolerated dose (MTD) strategies as compared with low dose, high density metronomic strategies (LDM) for tumors with different growth rates. Our results show that LDM strategies can outperform MTD strategies in total tumor cell reduction (TCR). The advantage is magnified for fast growing tumors that thrive on long periods of unhindered growth without chemotherapy drugs present and is not evident after a single cycle of chemotherapy, but grows after each subsequent cycle of repeated chemotherapy. The model supports the concept of designing different chemotherapeutic schedules for tumors with different growth rates and develops quantitative tools to optimize these schedules for maintaining low volume tumors. The evolutionary model we introduce in this paper is compared with regression data from murine models and shown to be in good agreement.Major Findings Model simulations show that metronomic (low dose, high density) therapies can outperform maximum tolerated dose (high dose, low density) therapies. This is due to the fact that tumor cell reduction is more sensitive to changes in dose density than changes in dose concentration, especially for faster growing tumors. This effect is negligible after a single cycle of chemotherapy, but magnified after many cycles. The model also allows for novel chemotherapeutic schedules and quantifies their performance according to tumor growth rate.